The conditional and reversible depletion of proteins by auxin-mediated degradation is a powerful tool to investigate protein functions in cells and whole organisms. However, its wider applications require fusing the auxin-inducible degron (AID) to individual target proteins. Thus, establishing the auxin system for multiple proteins can be challenging. Another approach for directed protein degradation are anti-GFP nanobodies, which can be applied to GFP stock collections that are readily available in different experimental models. Here, we combine the advantages of auxin and nanobody-based degradation technologies creating an AID-nanobody to degrade GFP-tagged proteins at different cellular structures in a conditional and reversible manner in human cells. We demonstrate efficient and reversible inactivation of the anaphase promoting complex/cyclosome (APC/C) and thus provide new means to study the functions of this essential ubiquitin E3 ligase. Further, we establish auxin degradation in a vertebrate model organism by employing AID-nanobodies in zebrafish.
Introduction
Conditional loss of function studies are fundamental to reveal specific protein functions in complex biological systems. The rapid degradation of proteins fused to an auxin-inducible degron (AID) enables the generation of conditional knockdowns at the protein level [1] [2] [3] [4] and thus belongs to the few approaches that enable determination of acute phenotypes in a reversible manner. Degradation requires the ectopic expression of the plant F-Box protein TIR1, which recruits proteins tagged with AID in an auxin-dependent manner to the SKP1-CUL1-F-Box (SCF) ubiquitin E3 ligases resulting in their ubiquitylation and proteasomal degradation. A caveat with this approach is however the need for genetic engineering as the AID needs to be site-specifically inserted into the alleles of each targeted protein. Further, it has been reported that fusion with the AID degron can destabilize the tagged protein 4 . So far, the auxin system has been established in a limited number of case studies including yeast 4 , nematodes 5 , flies 1 and human cell lines 3, 6, 7 . However, its feasibility in a vertebrate model organism remains to be shown and large-scale application of the AID system in animal remains challenging despite the advent of CRISPR/Cas9. deGradFP is an alternative approach to target proteins for degradation 8 and takes advantage of genetically encoded nanobodies that can recognize GFP-tagged proteins in living cells 9 . deGradFP employs a fusion of the anti GFP-nanobody vhhGFP4 10 to the F-box domain of the F-box protein Slimb enabling direct and effective GFPfusion protein removal in a SCF and proteasome-dependent manner in flies and human cell culture 8 . As the efficiency of deGradFP degradation has been shown to differ between model organisms deGradFP-like approaches that employ distinct degradation domains have been developed in nematodes 11 and zebrafish 12 . One advantage compared to the AID system are stock collections of endogenous proteins tagged with GFP or GFP-like proteins (e.g. YFP, Venus, Citrine), which are recognized by anti-GFP nanobodies. Such collections are readily available in model systems such as flies and zebrafish [13] [14] [15] and endogenous GFP-fusions are also increasingly used in human cell lines (this study, [16] [17] [18] [19] ). Hence, degradation technologies targeting GFP have the potential to become a widespread application in a multitude of experimental systems, especially in animal model organisms, due to the possibility to obtain homozygous GFP-trap alleles by breeding.
Compared to the AID system however, deGradFP and related nanobody-mediated degradation systems suffer from two key disadvantages. First, the induction of degradation is coupled to the de novo expression of the nanobody-F-box fusion and therefore only provides a rough temporal control. Second, degradation is not reversible as long as the nanobody-degron fusion protein is present, thus precluding experiments that depend on the transient inactivation of the target protein.
We reasoned that merging the two elements that provided reversibility of AID and specificity of nanobodydependent degradation would mitigate disadvantages of both technologies and provide a potent alternative degradation tool to address biological questions from the cellular to the organismal level. We show that expression of a customized AID-nanobody fusion in combination with TIR1 provides a powerful strategy to reversibly deplete GFP-tagged proteins localized to distinct cellular structures by ubiquitin-mediated proteolysis in an auxin-dependent manner. Comparing AID-nanobody-mediated degradation with established auxin and deGradFP technologies, we find that successful application and degradation efficiency of each system is contextdependent and differs for individual target proteins. By targeting endogenous ANAPC4, an essential subunit of the anaphase promoting complex/cyclosome (APC/C), we provide an example for which only the mAIDnanobody technology enables a reversible functional inactivation of this crucial cell cycle enzyme. Finally, we show that the auxin system can be applied to a vertebrate model organism by demonstrating effective degradation of GFP-tagged proteins by mAID-nanobodies in zebrafish.
Results

Development of a lysine-less mAID-nanobody
Protein degradation of GFP-fusion proteins by the auxin-inducible nanobody system ( Fig. 1 ) requires ectopic expression of the plant F-box protein TIR1 and an anti-GFP nanobody fused to the AID degron. To ensure efficient protein degradation in both, the nucleus and the cytoplasm, we first created HeLa and retina pigment epithelial cell lines (hTERT RPE-1) stably expressing TIR1 either tagged with a nuclear localization sequence (NLS) or a nuclear export sequence (NES) ( Supplementary Fig. 1a ).
Figure 1|
Auxin-dependent degradation of GFP-tagged proteins by an anti-GFP nanobody. Schematic illustration of AID-nanobody degradation. GFP-tagged proteins are recognized by an AID-nanobody fusion. Addition of auxin triggers recruitment of the SCF TIR1 ubiquitin E3 ligase. Ubiquitylation of the GFP fusion protein occurs at lysine residues present in GFP and/or the target protein leading to proteasomal degradation. AID, auxin-inducible degron; Cul1, Cullin-1; Rbx1, RINGbox protein 1; Skp1, S-phase kinase-associated protein 1; TIR1, transport inhibitor response 1; vhh-GFP4, anti-GFP nanobody.
To reduce the size of the AID-nanobody fusion, we first explored the potential of single (67 aa) and triple (201 aa) minimized AID (mAID) sequences reported to have a similar or superior efficiency compared to the full length AID 20 ( Supplementary Fig. 1b ). Monitoring the degradation of mAID-Venus reporters after the addition of indole-3-acetic acid (IAA) or the synthetic auxin analog 1-naphtaleneacetic acid (NAA, thereafter generally referred to as auxin), we found no significant difference in the degradation kinetics of either reporter suggesting that a single mAID was sufficient for efficient degradation in human cell lines (data not shown). Of note, triple mAID fused to Venus induced aggregate formation in HeLa and RPE-1 cells ( Supplementary Fig. 1c and data not shown) while single mAID did not. Consequently, we fused a single mAID labeled with a hemagglutinin (HA) epitope for detection onto the N-terminus of the anti-GFP nanobody vhhGFP4 8,10 creating mAID-vhhGFP4 ( Supplementary Fig. 1d ). To assess the stability of the mAID-nanobody fusion in response to auxin treatment, we inserted tetracycline-inducible mAID-vhhGFP into the TIR1-expressing HeLa cell line. Western blot analysis revealed the substantial depletion of mAID-vhhGFP4 in the presence of auxin ( Supplementary Fig. 1e ), indicating that SCF TIR1 ubiquitylated mAID-vhhGFP4 on one or several of the lysine residues present in mAID and/or vhhGFP4. We reasoned that replacing all lysine residues present in mAID-vhhGFP4 with structurally related arginine residues that cannot be ubiquitylated could provide a strategy to stabilize the mAID-vhhGFP4 and to direct SCF TIR1 activity exclusively towards GFP-fusion proteins. To examine if lysine to arginine mutagenesis has a functional impact on the ability of TIR1 to recognize mAID, we replaced all lysines present in mAID but not in vhhGFP4 (mAID K à R -vhhGFP4) ( Supplementary Fig. 1d ). The lysine-less mAID still supported degradation of the mAID K à R -vhhGFP4, presumably due to ubiquitylation of the remaining lysines present in vhhGFP4 ( Supplementary Fig. 1e ). This finding suggested that lysine to arginine mutagenesis did not impair the recognition of lysine-less mAID by TIR1. Mutagenesis of all lysines in vhhGFP4 further stabilized mAID K à R vhhGFP4 K à R (hereafter generally referred to as mAID-nanobody or mAID-vhhGFP) ( Supplementary Fig. 1e ).
To assess the functionality of the complete lysine-less mAID-nanobody, we first monitored its ability to degrade the GFP-like protein Venus. Adding auxin to a stable cell line expressing Venus and tetracycline-inducible mAIDnanobody resulted in Venus degradation in an auxin-and proteasome-dependent manner ( Fig. 2a , Supplementary Fig. 2a ). Degradation of Venus indicated that lysine mutagenesis in vhhGFP4 is not critical for nanobody binding to GFP or GFP-like proteins.
Thus, we conclude that due to its ability to solely target the fluorescent protein, the mAID-nanobody is in principle able to degrade any GFP-tagged protein independently of the availability of additional lysine residues present within the target protein. Quantifications show non-linear fit (one-phase decay) of (n=6, 0 tetracyline ± auxin; n=3, remaining concentrations). Note, images of -auxin, + auxin and 10 μM MG132-treated cells, degradation of Venus by deGradFP, and Western blot detection of mAID-nanobody expression during the titration are shown in Supplementary Fig. 2 .
Kinetics of Venus degradation by mAID-nanobodies
We observed a depletion of Venus by the mAID-nanobody with a half-life of ~97 minutes ( Fig. 2a ) and thus tested how this relates to degradation kinetics of a direct AID-Venus fusion protein. We fused wildtype mAID to the C terminus of Venus and quantified degradation efficiency by life cell imaging. Compared to degradation by the mAID-nanobody the direct fusion of mAID to Venus (Venus-mAID) resulted in ~4-fold faster degradation kinetics (t 1/2 = 21.18 minutes) (Figs. 2a, b, Supplementary Fig. 2a ). This result was confirmed by Western blot analysis ( Fig. 2c) . This difference might reflect the reduced complexity of a 2-component degradation system compared to our 3-component approach. Alternatively, it might be a consequence of the additional lysine residues present in wildtype mAID providing more potential ubiquitylation sites.
Next, we investigated how different expression levels of the mAID-nanobody affect degradation kinetics.
Therefore, we titrated mAID-nanobody expression over a 7-fold range in a using increasing tetracycline concentrations ( Fig. 2d , Supplementary Fig. 2b ) Time-lapse imaging after auxin addition revealed that differences in the levels of mAID-nanobody had a minor impact on the efficiency of Venus degradation ( Fig. 2d) once the levels of mAID-nanobody and the levels of Venus were in the same range ( Fig. 2d , Supplementary Fig.   2b ). Levels of mAID-nanobody that were below Venus levels resulted in partial degradation. We observed that at its highest expression the mAID-nanobody slowed Venus degradation kinetics slightly ( Fig. 2d , Supplementary   Fig. 2b ), possibly reflecting that an excess of free mAID-nanobody competes with target-bound nanobodies for binding to SCF TIR1 ( Fig. 2d , Supplementary Fig. 2b ).
Taken together, we conclude that the mAID-nanobody robustly targets Venus for degradation when enough nanobody is expressed, albeit at a slower rate than achieved by a direct Venus-mAID fusion. Nevertheless, these results show that our approach is a powerful tool for the inducible degradation of GFP and GFP-like proteins.
Conditional and reversible depletion of GFP-fusion proteins localized to distinct cellular compartments and structures by mAID-nanobodies
So far, we have shown that the mAID-nanobody enables degradation of the Venus protein, which diffuses freely in the nucleus and cytoplasm. To determine whether mAID-nanobodies are able to also target GFP-fusion proteins present at distinct subcellular locations and to assess if auxin removal allows protein recovery including re-established protein localization, we created three TIR1 cell lines expressing different fluorescent fusion proteins: (i) Venus-tagged Lamin A (Venus-LMNA), which integrates into the nuclear lamina, a complex filamentous meshwork beneath inner nuclear membrane ( Fig. 3a) ; (ii) Venus-tagged Cyclin D1 (CCND1-Venus), which localizes to both, the cytoplasm and nucleus (Fig. 3b ), and (iii) GFP-tagged Inner centromere protein INCENP (INCENP-GFP), which localizes to distinct DNA-associated structures (Fig. 3c ). The fact that INCENP-GFP is expressed from the endogenous promoter in context of a bacterial artificial chromosome (BAC) 21 further allowed us to evaluate degradation and recovery of an endogenously regulated protein in comparison to CMV promotor -driven Venus-LMNA and CCDN1-Venus. Quantification of substrate depletion showed that kinetics of auxin-dependent degradation varied among the analyzed target proteins: while CCDN1-Venus was degraded with a half-life of ~84 minutes, 50% depletion of Venus-LMNA required ~59 minutes and only ~21 minutes for INCENP-GFP ( Fig. 3d ). Of note, in all cases the fusion protein was degraded more efficiently than the Venus tag itself ( Fig. 2a ), suggesting that additional ubiquitylation sites present in the protein fused to GFP/Venus positively affected degradation kinetics. During degradation of INCENP-GFP we observed a population of cells with incomplete degradation and slower kinetics (t 1/2 = 28.87 minutes). These might reflect cells in which the transiently expressed nanobody became limiting during the experiment ( Fig. 3c, and Fig. 2 ).
We conclude that mAID-nanobody-mediated degradation can be achieved for GFP-fusion proteins in different cellular compartments. We observed rapid but individually varying degradation kinetics up to the rate observed for Venus-mAID ( Fig. 2b) or direct substrate-AID fusions in mammalian cells 3 . Importantly, the recovery of all substrates after auxin removal confirmed the reversibility of protein depletion in the presence of mAIDnanobodies.
mAID-nanobodies allow the rapid and reversible inactivation of the APC/C
A major potential application for mAID-nanobodies is the conditional and reversible inactivation of endogenous GFP-tagged proteins to reveal acute phenotypes of otherwise essential proteins. In addition, the ability to correlate the degree of depletion and the emerging phenotype in individual cells by microscopy can facilitate the analysis of cause-effect relationships. As a proof of principle for the inactivation of an endogenous protein by the mAID-nanobody, we chose ANAPC4 as a target. The following rationales drove this decision: (i) ANAPC4 is a subunit of the APC/C, which allows assaying recognition by mAID-nanobody even in the context of a large and compact 15-subunit protein complex of 1.5 MDa. (ii) APC/C-dependent destruction of mitotic cyclins A2 (CCNA2) and B1 (CCNB1) is essential for mitotic progression and consequently its efficient inactivation yields an easily detectable mitotic metaphase arrest once cells enter mitosis.
To enable ANAPC4 degradation by mAID-nanobodies, we inserted a 3xFlag-streptaviding binding peptide (SBP)-Venus tag into all alleles of the ANAPC4 gene in a HeLa cell line stably expressing TIR1 and tetracycline-inducible mAID-nanobody by CRISPR/Cas9-assisted homologous recombination ( Supplementary Fig. 3a ). Neither, expression of Flag-SBP-Venus-ANAPC4 or TIR1 alone nor of Flag-SBP-Venus-ANAPC4, TIR1 and mAID-nanobody together caused a growth defect compared to the parent cell line ( Supplementary Fig. 3b ). Furthermore, the intracellular localization of endogenous Flag-SBP-Venus-ANAPC4 (from here, Venus-ANAPC4) did not differ from the localization of untagged endogenous ANAPC4 ( Supplementary Fig. 3c ) and Venus-ANAPC4 incorporated equally well as the untagged ANAPC4 into the APC/C ( Supplementary Fig. 3d ). Together, this showed that the fusion protein is functional. Quantitative spatio-temporal analysis of Venus-ANAPC4 levels in single cells monitored over 3 hours after auxin supply showed efficient depletion of the protein ( Fig. 4a and Supplementary Movie 1). With a half-life of ~16 minutes, degradation in the nucleus was slightly more efficient than in the cytoplasm (28 minutes) ( Fig. 4b ).
Quantitative Western blot analysis confirmed the degradation kinetics established by live cell imaging ( Supplementary Fig. 3e , f) and suggested that degradation indeed removed the entire protein as judged by anti-ANAPC4 or anti-GFP detection ( Supplementary Fig. 3g ). Depleting Venus-ANAPC4 for 3 hours partially affected the protein levels of ANAPC2, ANAPC10 and ANAPC11, whereas the protein levels of all other tested APC/C subunits remained largely unchanged ( Supplementary Fig. 3h ). Judging APC/C overall integrity after Venus-ANAPC4 depletion by immunoprecipitating the unaffected ANAPC3 subunit indicated that removal of ANAPC4 caused a partial disassembly of the holoenzyme ( Supplementary Fig. 3i ). The observed decrease in protein levels of some APC/C subunits might reflect a reduced protein stability, which can be observed after disrupting the integrity of large molecular assemblies 22, 23 . However, we cannot exclude that the SCF TIR1 ubiquitylated in addition to ANAPC4 also neighboring APC/C subunits.
To investigate whether the degree of ANAPC4 depletion was sufficient to interfere with APC/C function, we monitored the accumulation of mitotic cells in asynchronously growing cells for 24h. In agreement with a strongly prolonged duration of mitosis ( Supplementary Fig. 3j ), we observed an increasing number of cells that were arrested at metaphase (Fig. 4c ). In addition, we noted elevated protein levels of mitotic cyclins CCNB1 and CCNA2 indicative of a mitotic arrest ( Fig. 4d ). Thus, the degradation of Venus-ANAPC4 by the mAID-nanobody efficiently abrogated the main function of the APC/C. Finally, we assessed if removal of auxin allowed Venus-ANAPC4 recovery and functional reconstitution of APC/C. Indeed, already 8 hours after auxin removal Venus-ANAPC4 levels recovered sufficiently to allow progression through mitosis ( Fig. 4e ) and pre-treatment Venus-ANAPC4 levels were reached after prolonged recovery ( Fig. 4f, g ).
We conclude that functional recovery of proteins after mAID-nanobody depletion is possible also for components of multi subunit protein complexes that partially disintegrate upon target protein depletion.
Degradation of endogenous ANAPC4 by mAID-nanobodies in comparison with AID and deGradFP systems
A direct fusion of mAID to Venus enabled faster degradation kinetics than using the mAID-nanobody in context of Venus alone (Fig. 2 ). However, monitoring the degradation of fluorescent fusion proteins revealed that mAIDnanobodies can achieve similar degradation rates ( Figs. 3 and 4) . To compare the degradation potential of mAIDnanobodies to a direct mAID-fusion in a biological relevant context we assessed Venus-ANAPC4 depletion and functional inactivation of the APC/C. We generated an endogenous mAID-Venus-ANAPC4 fusion in a cell line stably expressing TIR1 by CRISPR/Cas9-assisted homologous recombination ( Supplementary Fig. 4a , Supplementary Material and Methods). Western blot analysis of total cell lysates derived from two clones confirmed the expression of mAID-Venus-ANAPC4 ( Supplementary Fig. 4b ) and immunoprecipitation with anti-ANAPC3 antibodies indicated that the fusion protein incorporated similarly well as untagged ANAPC4 into the APC/C ( Supplementary Fig. 4c ). Of note, we observed mild differences in the expression level and intracellular localization of mAID-Venus-ANAPC4 compared to Venus-ANAPC4 and untagged ANAPC4. mAID-Venus-ANAPC4 levels were slightly higher and the protein localized more prominently to the cytoplasm ( Supplementary Figs. 4d and 3c). It is unlikely that this is due to the molecular size of the epitope tag on ANAPC4 because the mAID-Venus tag contains only four additional amino acids compared to the Flag-SBP-Venus tag. Indeed, Flag-SBP-Venus-ANAPC4 and mAID-Venus-ANAPC4 exhibited an almost identical migration behavior in SDS-PAGE as determined by Western blot analysis ( Supplementary Fig. 4b ). Since mAID-Venus-ANAPC4 properly incorporated into the APC/C and neither obvious growth defects were observed during two months of cell culture (data not shown) nor a consistent increase in the duration of mitosis ( Supplementary Fig. 4e ), we conclude that AID-Venus-ANAPC4 cells are suitable to compare the ability of mAID to degrade ANAPC4 and inactivate the APC/C side by side with mAID-nanobody. In addition, we assessed how the mAID-nanobody approach relates to deGradFP as an alternative nanobody degradation technology. To this end, we created isogenic tetracycline-inducible cell lines expressing deGradFP or deGradFP D Fbox 8 as a negative control in the background of the endogenous Venus-ANAPC4 expressing cell line described earlier. To assess the efficiency of all three systems, we simultaneously monitored Venus-ANAPC4 and mAID-Venus-ANAPC4 fluorescence in single cells by time-lapse microscopy for 24 hours, either after the addition of auxin (mAID-nanobody and mAID-Venus-ANAPC4) or after tetracycline-induced deGradFP expression. As previously observed, Venus-ANAPC4 was efficiently targeted for degradation by the mAID-nanobody within 3 hours of auxin addition (Fig. 5a ). At this time point neither cells with mAID-Venus-ANAPC4 nor cells with Venus-ANAPC4 targeted by deGradFP showed a prominent decrease in the fluorescence signal ( Fig. 5a, Supplementary Movie 2) .
Even 24 hours after induction of degradation, no decrease of mAID-Venus-ANAPC4, both by live cell imaging and by Western blot analysis of ANAPC4 levels in total cell lysates was observed (Fig. 5b, c) . To ensure that this result was not caused by a suppressor mutation within the SCF TIR1 -auxin system in the two clones we generated ( Supplementary Fig. 4 ), we rescued the mAID-Venus-ANAPC4 degradation with the mAID-nanobody. Indeed, expression of mAID-nanobodies resulted in efficient degradation of mAID-Venus-ANAPC4 in response to auxin in transiently transfected cells ( Supplementary Fig. 5a , Supplementary Movie 3). Of note, degradation occurred in cells containing a wide range of mAID-nanobody transcripts, indicative of a robust degradation system. In agreement, we observed auxin-dependent degradation of mAID-Venus-ANAPC4 in the two clones tested by
Western blot analysis of the total cell population ( Supplementary Fig. 5b ). We hypothesize that when directly fused to Venus-ANAPC4 in context of the large APC/C assembly, the mAID degron is not accessible for recognition by the SCF TIR complex. Binding of the mAID-nanobody to Venus might bridge the interaction and recruit SCF TIR to mAID-Venus-ANAPC4.
In addition, the alternative nanobody-based approach deGradFP but not deGradFP D Fbox targeted Venus-ANAPC4 for degradation. However, in contrast to the mAID-nanobody, the degradation kinetics of deGradFP were slower and more heterogeneous (Supplementary Movie 2) and reduced the Venus-ANAPC4 fluorescence in the total cell population by only ~35% (Fig. 5b and Supplementary Fig. 6a, b) . The lower overall degradation efficacy of deGradFP might be a consequence of the additional time required for expression and folding of the deGradFP protein. Further, the protein levels of deGradFP but not of the mAID-nanobody were strongly stabilized by proteasome inhibition with MG132 ( Supplementary Fig. 6c, d ), suggesting that deGradFP is ubiquitylated and degraded and therefore might become limiting.
We conclude that from the three evaluated approaches only the mAID-nanobody inactivated the APC/C sufficiently to prevent degradation of mitotic substrates such as CCNB1 and CCNA2 ( Figs. 4d and 5c ). Hence, at least in the context presented here, the mAID-nanobody is the method of choice to functionally inactivate the APC/C.
Auxin-dependent degradation of GFP-tagged proteins by mAID-nanobodies in zebrafish
Finally, we assessed whether auxin-mediated degradation by the mAID-nanobody is also effective beyond human cell lines. We chose zebrafish as a vertebrate organism, since it is an outstanding animal model for timelapse imaging approaches and thus would especially benefit from a traceable and reversible protein degradation approach. Previously, anti-GFP nanobody 12 and HaloTag 24 degradation systems were used in zebrafish, however inducible and reversible knockdown strategies are still in their infancies. We first established the concentration of IAA zebrafish embryos tolerated during development. Whereas application of IAA up to 2 mM did not result in any visible developmental defect, 5 mM IAA slightly delayed development ( Supplementary Fig. 7a ). Consistent with previous studies in other model organisms 2,5 , we therefore used 0.5 mM IAA or 0.5 mM NAA for all subsequent experiments. To assess if auxin-based protein degradation with the mAID-nanobody is possible in zebrafish, we first used a transgenic line expressing proliferative cell nuclear antigen tagged with GFP (GFP-PCNA). We provided the degradation system by injecting a mix of RNAs expressing mAID-nanobody, TIR1 and the transfection control H2B-RFP into embryos in a mosaic fashion. We added 0.5 mM IAA at 4-5 hpf and monitored GFP-PCNA degradation in retinal neuroepithelium (Fig. 6a ). GFP-PCNA was robustly degraded at 22 hours post fertilization (hpf) to less than 20% of its original levels, while only negligible protein degradation occurred in the absence of IAA (Fig. 6b ). In case of NAA, we observed even more robust degradation of GFP-PCNA to just 12% of its original levels ( Fig. 6c ), suggesting NAA as the preferred molecule for triggering the TIR1-AID interaction in zebrafish. Next, we tested the kinetics of GFP-PCNA degradation by adding NAA to embryos at 22 hpf and followed the GFP fluorescence by time-lapse imaging in S phase cells with and without the degradation system ( Fig. 6d) . A decrease in GFP signal was apparent from 60 min after NAA addition and after 3 hours GFP-PCNA reached low levels that were comparable to long-term incubation of embryos with IAA or NAA for 18 hours (Fig. 6b-d) . We observed some differences in degradation efficacy among cells ( Fig. 6d and Supplementary Fig. 7b ) most likely reflecting that differing amounts of RNAs are present in individual cells due to differential distribution upon cell division.
To investigate if degradation is also possible in other cellular compartments, we used transgenic lines expressing GFP fused to (i), the Lamina-associated polypeptide 2 (GFP-LAP2b), an inner nuclear membrane protein; (ii) GFP-Utrophin, an F-actin binding probe that is recruited predominantly to the cell cortex and (iii), Myosin, light chain 12, genome duplicate 1-GFP (Myl12.1-GFP), a light chain of non-muscle myosin II that colocalizes with actin filaments in the cytoplasm. In all cases, adding IAA resulted in robust protein degradation (Fig. 6e ).
Quantification of GFP-LAP2b reiterated that NAA was more potent than IAA for protein depletion in the zebrafish (Fig. 6f ). Finally, we wondered whether GFP-tagged proteins could be recognized by the AID-nanobody during or shortly after translation. Thus, we tested whether proteins localized to compartments without SCF TIR1
and proteasomal activity such as mitochondria might be subject to mAID-nanobody-driven protein depletion using a zebrafish line expressing GFP fused to a mitochondrial matrix localization sequence (mls-GFP). Indeed, we observed a reduction of GFP fluorescence after IAA addition (Fig. 6g ), suggesting that mls-GFP is targeted for degradation immediately after translation and before it is translocated into mitochondria. Since mls does not contain any lysine residues, this result underlines that mAID-nanobodies allow GFP-fusion protein degradation exclusively based on GFP.
Taken together, we demonstrate that the auxin system can be applied to a vertebrate model organism thus is applicable beyond human cell lines. By using zebrafish as a proof of principle, we show that the mAID-nanobody can target GFP-tagged proteins localized to different subcellular structures for degradation.
Discussion
Instant but reversible inactivation of proteins is key to reveal acute phenotypes that otherwise might be masked by compensation or a dominant terminal phenotype. This holds especially true for proteins or protein complexes such as the APC/C that are essential for proliferation, but fulfill beyond this canonical role additional crucial functions, i.e. during development or in quiescent and post-mitotic cells [25] [26] [27] . Therefore, several strategies have been developed that employ the ubiquitin proteasome system present in all eukaryotic cells to target proteins for degradation, either by the addition of cell-permeable molecules 2,28 , the expression of genetically encoded nanobodies 8, 11, 12 or more recently, by the injection of antibodies into human cells or mouse oocytes 23 . All of these approaches have their own advantages and disadvantages and their successful application depends on the targeted protein(s) and the experimental model of choice.
Here, we present a mAID-nanobody to degrade GFP-tagged proteins that combines advantages of existing auxin and nanobody-based technologies. Utilizing SCF TIR1 , the mAID-nanobody employs the same intracellular degradation machinery established by the classical auxin system and thus shares its key features By directing SCF TIR activity towards the GFP, the mAID-nanobody can in principle target any protein for degradation regardless of their sequence, size and structure. Even a protein localized to a compartment with no SCF activity such as mitochondria can be degraded (Fig. 6) , presumably by co-translationally binding of the mAID-nanobody to the target once the GFP epitope is folded. Degradation of the model substrate Venus indicated that the classical auxin system enables faster degradation kinetics than the mAID-nanobody (Fig. 2) . In the context of more biological relevant fusion proteins, mAID-nanobody depletion achieved half-lives ranging from ~16-83 minutes ( Figs. 3 and 4) , which we expect to be suitable for most experimental designs.
As the AID degron is provided in trans by the nanobody our technology does not require time-consuming fusion of AID degrons to the protein(s) of choice. Thereby, mAID-nanobodies can take advantage of GFP stock collections that exist for several model organisms [13] [14] [15] and the increasing number of homozygous fluorescent knock-ins in cell culture [16] [17] [18] [19] . Providing the mAID in trans by the nanobody might have further benefits over a direct fusion of the degron sequence to the target protein in certain cases. First, titratable expression levels of the mAID-nanobody provides additional means to control the extent of target degradation. Significantly lower levels of mAID-nanobody than the target partially decreased Venus expression to a steady level that was maintained for at least 7 hours after auxin addition (Fig. 2) . This feature might facilitate establishing thresholds at which the concentration of the target protein becomes limiting for a specific biological function. Second, previous studies raised concerns that AID fusion can destabilize substrate proteins 4 , and we observed that fusing mAID to Venus or Venus-ANAPC4 partially altered the localization of the fusion protein. Although adding the mAID degron to Venus is not predicted to hinder free diffusion of the 37kDa fusion protein through nuclear pore complexes 29 , mAID-Venus was localized more pronouncedly to the cytoplasm than Venus (Fig. 2) . Similarly, mAID-Venus-ANAPC4 was enriched in the cytoplasm compared to Venus-ANAPC4 and untagged ANAPC4 (Figs. 4 and 5, Supplementary Figs. 3 and 4) . In contrast, the presence of the mAID-nanobody had neither an effect on the localization of Venus nor of Venus-ANAPC4 ( Figs. 2 and 4) , nor affected it the viability of Venus-ANAPC4 expressing cells ( Supplementary Fig. 3 ). Third, recruiting SCF TIR1 by the mAID-nanobody might be advantageous for degradation of subunits in large protein complexes such as the APC/C, where a directly fused AID degron might not be accessible to the SCF TIR1 complex ( Fig. 5 and Supplementary Fig. 5 ).
Compared to existing anti-GFP nanobody degradation strategies based on deGradFP 8, 11, 12 , the major advantage of the mAID-nanobody is the ability to rapidly induce the degradation of the target protein but also to allow recovery after auxin removal. Further, the stabilization of the mAID-nanobody by lysine mutagenesis ensures that the amount of nanobody does not become limiting as it is the case for antibody-based degradation 23 and likely deGradFP in our experimental system ( Supplementary Fig. 6 ). By virtue of endogenously tagged Venus-ANAPC4, we show that mAID-nanobodies rapidly decrease Venus-ANAPC4 levels to an extent that causes a pronounced mitotic arrest. In contrast, even extended expression of deGradFP for 24 hours did not reduce Venus-ANAPC4 levels by more than ~35% and failed to cause a mitotic phenotype (Fig. 5 ). We observed that deGradFP is strongly stabilized by proteasome inhibition (Supplementary Fig. 6 ). Hence, similar to the first version of mAID-vhhGFP4 with lysine residues ( Supplementary Fig. 1 ), the vhhGFP4 containing deGradFP might be ubiquitylated and degraded. At least with the tetracyline-inducible system we used here, the achieved degree of deGradFP expression might not be sufficient to completely deplete Venus-ANAPC4.
By establishing mAID-nanobody degradation in zebrafish we demonstrate that the auxin system can be applied to a vertebrate model organism. As observed in human cells efficient degradation in zebrafish might require optimization of mAID-nanobody expression with respect to the abundance of targeted protein, which can be easily achieved by injecting different amounts of RNA. Because injected RNAs are getting depleted during animal development RNA-based delivery of the mAID-nanobody system is restricted in time. In the retina, we have observed efficient degradation up to 26 hours post injection. Creation of a transgenic line expressing TIR1 and an inducible mAID-nanobody would greatly augment applications in zebrafish and other animal models. Since the auxin system has been established in yeast 2,4 , flies 1 and nematodes 5 , we predict that mAID-nanobody technology can readily be implemented in a wide range of animal models.
In summary, we present an approach in which ectopic expression of TIR1 and a customized mAID-vhhGFP fusion provide a powerful strategy for the conditional and reversible degradation of potentially any GFP/GFP-like fusion protein. mAID-nanobodies enable loss of function studies of endogenous GFP-tagged proteins and thus are especially attractive to animal models where GFP-trap stock collections exist and homozygosity of alleles can be easily achieved by breeding. Facilitated by advances in genome engineering, the number of endogenously GFP-tagged lines in different model organisms and in human cell culture models will only increase in the future.
mAID-nanobody degradation may also be applied to overexpressed GFP-fusions, e.g. to inactivate dominant negative mutants. Because knockouts are comparably easier to obtain than knock-in's, the existing GFP BAC libraries in human cells 30 provide an additional resource for loss of function studies by mAID-nanobodies, given that endogenous alleles are ablated by CRISPR/Cas9 or alternative methods. Notably, our approach is not restricted to GFP and GFP-like proteins as nanobodies directly recognizing endogenous proteins 31 or other fluorescent proteins are available 32 . Finally, we present a rationale of how nanobodies in general can mediate ligand-inducible protein interactions without the need of genetically modifying the target of interest, thereby enabling applications beyond auxin-dependent protein degradation. DNA constructs. Codon-optimization of rice TIR1 for mammalian expression has been described previously 6 . To visualize mAID-vhhGFP expression in transient transfection experiments the mAID-vhhGFP sequence was cloned downstream of an IRES element of CMV-driven mCherry fused at its N terminus to the N-terminal importin b binding domain (IBB) creating IBB-mCherry-IRES-mAID-vhhGFP in a pIRESpuro backbone (Thermo Fisher Scientific). LMNA was amplified from a plasmid encoding GFP-Lamin A 33 and cloned onto the C-terminus of 3xHA-Venus. Flag-murine CCND1 was amplified from a CCND1-CDK2 fusion 34 XhoI-3xFlag-SBP-Venus-15-alanine-glycine-linker-HindIII fragment was amplified from synthetic DNA and cloned together with both homology arms into the NotI sites of pAAV-MCS (Stratagene). For mAID-Venus-ANAPC4 targeting the sequence encoding 3xFlag-SBP was exchanged with mAID using the EcoRI and XhoI sites present in the 3xFlag-SBP-Venus nucleotide sequence.
Supplementary figures and legends
To generate zebrafish constructs Gateway cloning (Thermo Fisher Scientific) based on the Tol2 kit 35 was used.
Tol2-bactin:GFP-PCNA, eGFP-PCNA middle entry clone 36 was combined with the beta-actin promoter 5′ entry clone 35 and pTol2+pA R4-R2 backbone 37 . Tol2-bactin:GFP-LAP2b, the LAP2b 3′ entry clone was created by amplifying Lap2b from pmRFP_LAP2beta_IRES_puro2b (gift from Daniel Gerlich, Addgene plasmid #21047) using forward 5′-ggggacagctttcttgtacaaagtggctCTGTACAAGTACTCAGATCTCGAGC-3′ together with reverse 5′-ggggacaactttgtataataaagttgcTCAGTTGGATATTTTAGTATCTTGAAGAAAATTAGTG -3′ oligonucleotides) followed by recombination with the beta-actin promoter 5′ entry clone, GFP middle entry clone, and pTol2+pA R4-R3 backbone 35 . The HA-mAID K à R -vhhGFP4 K à R , Flag-myc-NES-TIR1, NLS-TIR-HA and mKate2 were subcloned into pCS2+ vector for RNA production. The H2B-RFP in pCS2+ was published previously 38 . The plasmids and their sequences will be available from Addgene.
Generation of cell lines. A Neon Transfection system (Thermo Fisher Scientific) was employed to deliver DNA constructs to generate all cell lines. Stable HeLa FRT/TO and RPE-1 (hTERT) FRT/TO cell lines expressing TIR1, Venus, Venus-LMNA, CCND1-Venus were generated by random integration and selection with puromycin (0.5 µg/ml) or blasticidin (5 µg/ml). Stable clones expressing tetracycline-inducible Venus-AID, mAID-vhhGFP4, deGradFP and deGradFP D Fbox constructs were cloned into pCDNA5/FRT/TO vectors (see above) and integrated into an FRT site using the Flp-In system (Thermo Fisher Scientific) according to the manufactures instructions, followed by selection with neomycin (400 µg/ml) and isolation of single clones. mAID-vhhGFP4 constructs were inserted into the FRT site of same single parent RPE-1 (hTERT) or HeLa clone expressing already TIR1 to ensure an isogenic background. mAID-nanobodies expression in Venus-LMNA cells was induced for 24 hours by 10-20 ng/ml tetracycline and by 1 µg/ml tetracycline for CCND1-Venus or Venus cells unless otherwise indicated. For
Venus-ANAPC4 degradation the residual tetracycline in the medium was sufficient for degradation. deGradFP and deGradFP D Fbox expression was induced by 1 µg/ml tetracycline for the indicated time. Site-specific integration of 3×Flag-SBP-Venus into ANAPC4 loci was facilitated by CRRISPR/Cas9-mediated homologues recombination using a gRNA targeting the N-terminus of the ANAPC4 gene (5'-ctgactggggtgtcgttgca-3'). Briefly, NLS-Flag-linker-Cas9 6 and the pAAV-3xFlag-SBP-Venus or pAAV-mAID-Venus targeting constructs (see above)
were co-electroplated into HeLa FRT/TO cells followed by one week recovery and expansion of cells.
Subsequently, single Venus-positive integrands were identified and sorted by flow cytometry. PCR and sequencing analyses confirmed that in the case of 3xFlag-SBP-Venus-ANAPC4 targeting all ANAPC4 alleles were successfully targeted, whereas in the case of mAID-Venus-ANAPC4 only one out of three ANAPC4 alleles was targeted. A second allele displayed a truncation removing the complete first exon including all potential start codons, while a third allele featured a deletion of 10 base pairs upstream of the ANAPC4 start codon that included the acceptor splice site of the adjacent exon-intron border. Analyses of ANAPC4 levels in total lysates and of ANAPC4 incorporation into the APC/C ( Supplementary Fig. 4 ) by Western blot suggested that the tagged allele encodes for the only ANAPC4 protein being expressed.
Zebrafish husbandry. Wild type strain TL (RRID:ZIRC_ZL86) of zebrafish was used. Adult fish were maintained and bred at 26°C. Embryos were raised at 28.5°C. Embryos were incubated in E3 medium supplemented with 0.2 mM 1-phenyl-2-thiourea (Sigma-Aldrich P7629) from ~5 hours post fertilization (hpf) to prevent pigmentation.
All animal work was performed in accordance with EU directive 2010/63/EU as well as the German Animal Welfare Act.
Transgenic zebrafish lines. The GFP-PCNA line Tg(bactin:GFP-PCNA), ubiquitously expressing the GFP-tagged human proliferating cell nuclear antigen (PCNA), and the GFP-LAP2b line Tg(bactin:GFP-LAP2b), ubiquitously expressing the GFP-tagged rat lamina-associated polypeptide 2 were created by injection of 1 nl of the Tol2
